Market Place
Sourcing Support
Recursion Doses First Patient in Phase 1/2 Study of REC-1245
03 Dec 2024 //
GLOBENEWSWIRE
Recursion And Exscientia Combine To Advance AI Drug Discovery
20 Nov 2024 //
GLOBENEWSWIRE
Recursion Releases OpenPhenom-S/16 in Google Cloud Model Garden
12 Nov 2024 //
GLOBENEWSWIRE
Recursion Reports Q3 2024 Financials & Business Updates
06 Nov 2024 //
GLOBENEWSWIRE
Recursion Doses First Patient In Phase 2 Study Of REC-3964
22 Oct 2024 //
GLOBENEWSWIRE
Recursion Gets FDA Clearance for REC-1245 New Drug
02 Oct 2024 //
GLOBENEWSWIRE
Angle PLC Announces Agreement with Recursion Pharmaceuticals
19 Sep 2024 //
ACCESSWIRE
Nvidia-backed Recursion`s shares fall on mixed data for rare disorder drug
04 Sep 2024 //
REUTERS
AI biotechs Exscientia and Recursion agree $688m merger
10 Aug 2024 //
PHARMAPHORUM
Recursion Reports Q2 2024 Results And Provides Business Updates
08 Aug 2024 //
GLOBENEWSWIRE
Recursion Provides Updates And Reports Q2 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Helix and Recursion innovate drug discovery through clinico-genomic data.
24 Jun 2024 //
BUSINESSWIRE
Recursion Q1 2024 Results And Business Updates
09 May 2024 //
GLOBENEWSWIRE
Ex-Recursion team launches Leash Bio, challenging AI field
04 Apr 2024 //
ENDPTS
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2023 Earnings Call Transcript
27 Feb 2024 //
FINANCE YAHOO
Recursion to Host Public L(earnings) Call on February 27
20 Feb 2024 //
PRESS RELEASE
Altitude Lab Startups Raise Over $120M in Capital
24 Jan 2024 //
PRESS RELEASE
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Conference
08 Jan 2024 //
PRESS RELEASE
Recursion Pharma spikes after licensing deal with Bayer
04 Jan 2024 //
PRESS RELEASE
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
PRESS RELEASE
Bayer and Recursion focus research collaboration on Oncology
10 Nov 2023 //
PRESS RELEASE
Recursion Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Recursion Launches Valence Labs at ICML
26 Jul 2023 //
PRESS RELEASE
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals
18 Jul 2023 //
FOOL
Recursion Announces Collaboration and $50 Million Investment from NVIDIA
12 Jul 2023 //
GLOBENEWSWIRE
Altitude Lab Relocates to Gateway’s BioHive Hub
25 May 2023 //
PRESS RELEASE
Recursion stock extends gains in AI-led rally
23 May 2023 //
SEEKING ALPHA
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
16 May 2023 //
PRESS RELEASE
Recursion to acquire two Canadian drug discovery startups
09 May 2023 //
BIOPHARMADIVE
Recursion Provides Business Updates and Reports 1Q 2023 FYR
08 May 2023 //
GLOBENEWSWIRE
Recursion acquires two AI-based drug discovery companies in $87.5M deal
08 May 2023 //
ENDPTS
Recursion to Participate in Upcoming Investor Conferences
02 May 2023 //
PRESS RELEASE
Recursion Provides Reports Third Quarter 2022 Financial Results
08 Nov 2022 //
PRESS RELEASE
Recursion to Participate in Upcoming Investor Conferences
02 Nov 2022 //
PRESS RELEASE
Recursion dumps rare disease asset while raking in $150M
26 Oct 2022 //
FIERCEBIOTECH
Recursion Announces $150M Private Placement to New and Existing Investors
25 Oct 2022 //
PRNEWSWIRE
Recursion discreetly culls a rare disease program to focus on cancer
25 Oct 2022 //
ENDPTS
Recursion Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
PRNEWSWIRE
Recursion is Granted EU Orphan Drug Designation for REC-4881
21 Jul 2022 //
PRNEWSWIRE
Recursion to Participate in Upcoming Investor Conferences
02 Jun 2022 //
PRNEWSWIRE
Recursion Reports First Quarter 2022 Financial Results
10 May 2022 //
PRNEWSWIRE
Recursion is Granted FTD for REC-4881 for Familial Adenomatous Polyposis
11 Apr 2022 //
PRNEWSWIRE
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
30 Mar 2022 //
PRESS RELEASE
Recursion Publishes First Environmental, Social and Governance (ESG) Report
24 Mar 2022 //
PRESS RELEASE
Recursion Reports Fourth Quarter and Fiscal Year 2021 Financial Results
23 Mar 2022 //
PRNEWSWIRE
Recursion Begins Enrollment in Phase 2 Trial in Cerebral Cavernous Malformation
18 Mar 2022 //
PRESS RELEASE
Recursion to Participate in Upcoming Investor Conferences
04 Mar 2022 //
PRESS RELEASE
Recursion Provides Updated Guidance on Clinical Trial Starts
03 Mar 2022 //
PRNEWSWIRE
Recursion Collaborates with Roche and Genentech in Neuroscience and Oncology
07 Dec 2021 //
PRNEWSWIRE
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential
06 Dec 2021 //
YAHOO
Enveda Biosciences Hires New Chief Platform Officer
18 Oct 2021 //
BUSINESSWIRE
Recursion`s REC-2282 Granted FDA Fast Track Designation For NF2
07 Oct 2021 //
RTTNEWS
Recursion Announces Multi-Year Collaboration with Mila
23 Jun 2021 //
PRNEWSWIRE
Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling
25 May 2021 //
PRNEWSWIRE
Recursion Reports First Quarter 2021 Financials and Provides Business Updates
12 May 2021 //
PRNEWSWIRE
Recursion Pharmaceuticals Announces Closing of Initial Public Offering
21 Apr 2021 //
PRNEWSWIRE
Recursion Pharmaceuticals Jumps in Debut After $436 Million IPO
16 Apr 2021 //
BNNBLOOMBERG
AI drug prospector Recursion bumps IPO up (again) to $374M
16 Apr 2021 //
FIERCEBIOTECH
Recursion lays out $300M+ goal in IPO terms; Evotec and Bristol Myers
14 Apr 2021 //
GLOBNEWSWIRE
Recursion Pharmaceuticals Raises $239 Million And Partners With Bayer
08 Sep 2020 //
FORBES
